Comparative Pharmacology
Head-to-head clinical analysis: FLAXEDIL versus ZEMURON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAXEDIL versus ZEMURON.
FLAXEDIL vs ZEMURON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FLAXEDIL (gallamine triethiodide) is a nondepolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at nicotinic receptors at the neuromuscular junction, preventing muscle contraction.
Rocuronium is a nondepolarizing neuromuscular blocking agent that competitively binds to nicotinic acetylcholine receptors at the motor endplate, preventing acetylcholine from inducing muscle contraction.
0.08-0.12 mg/kg IV bolus for neuromuscular blockade; additional doses of 0.01-0.02 mg/kg as needed.
0.6-1.2 mg/kg IV bolus for intubation; maintenance 0.1-0.2 mg/kg IV as needed for neuromuscular blockade.
None Documented
None Documented
The terminal elimination half-life of gallamine is approximately 2-4 hours in patients with normal renal function. This half-life is inversely related to creatinine clearance, and may be prolonged to 12-24 hours or more in patients with renal impairment, leading to cumulative effects and prolonged neuromuscular blockade.
Terminal elimination half-life is approximately 2.3 hours (range 1.7-3.1 hours) in adults with normal renal function. Clinical context: May be prolonged in hepatic or renal impairment.
Flaxedil (gallamine triethiodide) is excreted primarily unchanged by the kidneys via glomerular filtration. Approximately 90-95% of an administered dose is eliminated in urine within 24 hours, with the remainder excreted in feces (<5%) via biliary elimination.
Primarily renal (70-80% as unchanged drug and metabolites) and biliary (20-30% as unchanged drug and metabolites).
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent